See every side of every news story
Published Updated

Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection

Summary by STAT
A phase 3 trial is now planned for the new formulation of lenacapavir, which could advance once-yearly medicines for HIV and other diseases.

10 Articles

All
Left
1
Center
1
Right
1
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
33% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

myscience.org broke the news in on Tuesday, March 11, 2025.
Sources are mostly out of United Kingdom (1)

Similar News Topics

You've reached the limit of your daily free article reads.

Join us as a member to unlock exclusive access to diverse content.

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.